Streetbeat News

Revenues

OKE

Analysts have provided diverse ratings for ONEOK (NYSE:OKE) with a range from bullish to bearish over the last three months. The average 12-month price target for OKE has increased by 6.82% to $82.36. Recent analyst actions include upgrades and raised price targets by firms such as Wells Fargo, Stifel, and Morgan Stanley, reflecting a positive outlook on the company. Despite this, ONEOK faces challenges in revenue growth, net margin, ROE, and ROA, indicating potential hurdles in financial performance.

Portfolio Pulse from Benzinga Insights

May 02, 2024 | 9:01 pm

WTRG

Essential Utilities (NYSE:WTRG) reported Q1 earnings of $0.97 per share, surpassing the $0.77 estimate, a 34.72% increase from last year. However, sales of $612.07M fell short of the $750.08M estimate, marking an 18.40% miss and a 15.75% decrease from the previous year.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 9:00 pm

SRPT

Sarepta Therapeutics (NASDAQ:SRPT) received mixed analyst ratings in the latest quarter, with 14 analysts offering insights. The ratings ranged from bullish to indifferent, with no bearish perspectives. The average 12-month price target for SRPT is now $157.21, up 8.14% from the previous $145.38, indicating a positive outlook from analysts. Sarepta Therapeutics, a biotech company focusing on rare diseases, showed a revenue growth of 53.54% and faces challenges in profitability and debt management.

Portfolio Pulse from Benzinga Insights

May 02, 2024 | 9:00 pm

SFM

Sprouts Farmers Market (NASDAQ:SFM) received mixed analyst ratings, with a shift towards more bearish views in the last 30 days. The average 12-month price target is $58.12, reflecting a 12.03% increase from the previous target. Financial performance shows positive revenue growth and strong profitability metrics, despite a lower market capitalization compared to industry peers.

Portfolio Pulse from Benzinga Insights

May 02, 2024 | 9:00 pm

CHRW

C.H. Robinson Worldwide (NASDAQ:CHRW) was analyzed by 8 analysts, showing a shift towards a more bearish sentiment with 3 indifferent and 5 somewhat bearish ratings recently. The average 12-month price target was adjusted to $74.25, a slight decrease of 0.67%. The company's financial performance indicates challenges with a -16.68% revenue growth decline, yet it maintains strong profitability metrics such as a 0.73% net margin and exceptional ROE and ROA figures. Analyst actions varied, with some raising and others lowering their price targets and ratings.

Portfolio Pulse from Benzinga Insights

May 02, 2024 | 9:00 pm

MSB

Mesabi Trust (NYSE:MSB) received a total royalty payment of $5,059,648 from Cleveland-Cliffs Inc. (Cliffs) on April 30, 2024, for iron ore shipments from Silver Bay, Minnesota during Q1 2024. The payment includes base and bonus royalties based on the volume of iron ore shipped, which was 1,006,692 tons, a significant increase from zero tons shipped in Q1 2023. The variations in royalty payments are influenced by multiple factors including Cliffs' operational decisions and general economic conditions.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 8:59 pm

HUN

Huntsman Corporation reported an improvement in Q1 due to higher sales volumes and improved margins, and expects these positive trends to continue into a seasonally stronger Q2.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 8:55 pm

EBS

Emergent BioSolutions, Inc. (NYSE:EBS) reported Q1 earnings of 59 cents per share, surpassing analyst expectations of an 83-cent loss, with sales of $300.4 million beating estimates by 33.81%. The company announced operational changes including facility closures and workforce reductions expected to save $80 million. Emergent raised its 2024 revenue guidance to $1 billion-$1.1 billion. Shares closed 70.9% higher at $3.30.

Portfolio Pulse from Erica Kollmann

May 02, 2024 | 8:55 pm

DKNG

DraftKings Inc (NASDAQ:DKNG) reported Q1 earnings with a revenue of $1.18 billion, a 53% increase year-over-year, surpassing the consensus estimate of $1.12 billion. EPS was 3 cents, beating the expected loss of 28 cents per share. The company attributes its revenue growth to customer engagement, acquisition, and new territory launches, with monthly unique payers up 23% year-over-year. DraftKings raised its 2024 revenue guidance to $4.8 billion to $5 billion and adjusted EBITDA guidance to $460 million to $540 million. The company is also planning to launch in Puerto Rico and highlighted potential expansions with legislation in nine jurisdictions.

Portfolio Pulse from Chris Katje

May 02, 2024 | 8:54 pm

STEM

Stem has revised its FY24 revenue guidance downwards from $600M-$700M to $567M-$667M, against an estimate of $672.29M. This adjustment is attributed to a $33M reduction in revenue. Despite this, the company maintains its previous guidance for non-GAAP Gross Margin, Adjusted EBITDA, Bookings, CARR, and Operating Cash Flow. The revised revenue forecast is detailed by quarterly performance percentages.

Portfolio Pulse from Benzinga Newsdesk

May 02, 2024 | 8:53 pm